- Home
- SBCF vs CELC Comparison
SBCF vs CELC Comparison
Compare SBCF & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBCF
- CELC
- Stock Information
- Founded
- SBCF 1926
- CELC 2011
- Country
- SBCF United States
- CELC United States
- Employees
- SBCF N/A
- CELC N/A
- Industry
- SBCF Major Banks
- CELC Medical Specialities
- Sector
- SBCF Finance
- CELC Health Care
- Exchange
- SBCF Nasdaq
- CELC Nasdaq
- Market Cap
- SBCF 3.0B
- CELC 3.1B
- IPO Year
- SBCF N/A
- CELC 2017
- Fundamental
- Price
- SBCF $30.43
- CELC $92.18
- Analyst Decision
- SBCF Buy
- CELC Strong Buy
- Analyst Count
- SBCF 3
- CELC 6
- Target Price
- SBCF $31.00
- CELC $90.00
- AVG Volume (30 Days)
- SBCF 569.0K
- CELC 1.3M
- Earning Date
- SBCF 10-27-2025
- CELC 11-12-2025
- Dividend Yield
- SBCF 2.50%
- CELC N/A
- EPS Growth
- SBCF 23.57
- CELC N/A
- EPS
- SBCF 1.68
- CELC N/A
- Revenue
- SBCF $556,541,000.00
- CELC N/A
- Revenue This Year
- SBCF $32.60
- CELC N/A
- Revenue Next Year
- SBCF $31.03
- CELC N/A
- P/E Ratio
- SBCF $18.13
- CELC N/A
- Revenue Growth
- SBCF 12.63
- CELC N/A
- 52 Week Low
- SBCF $21.36
- CELC $7.58
- 52 Week High
- SBCF $32.33
- CELC $94.06
- Technical
- Relative Strength Index (RSI)
- SBCF 48.34
- CELC 78.54
- Support Level
- SBCF $30.25
- CELC $72.05
- Resistance Level
- SBCF $31.74
- CELC $75.02
- Average True Range (ATR)
- SBCF 0.84
- CELC 4.49
- MACD
- SBCF -0.03
- CELC 0.92
- Stochastic Oscillator
- SBCF 37.75
- CELC 91.48
About SBCF Seacoast Banking Corporation of Florida
Seacoast Banking Corp of Florida is a holding company for Seacoast National Bank. The company provides integrated financial services including commercial and consumer banking, wealth management, and mortgage and insurance services to customers across Florida, and through mobile and online banking solutions. In addition, it provides services such as treasury management, brokerage and credit facilities.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.